EUVIMEDEUVIMED entdecken
Crossref

Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis

Shohei Yamamoto iD, Kouki Matsuda, Kenji Maeda, Kumi Horii, Kaori Okudera, Yusuke Oshiro, Natsumi Inamura, Takashi Nemoto, Junko S Takeuchi, Yunfei Li, Maki Konishi, Kiyoto Tsuchiya und 8 weitere

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Shohei Yamamoto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Post-Acute COVID-19 Syndrome, COVID-19. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Japan Health Research Promotion Bureau, National Center for Global Health and Medicine, Abbott Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data are limited on the role of preinfection humoral immunity protection against Omicron BA.5 infection and long coronavirus disease (COVID) development.

Methods

We conducted nested case-control analysis among tertiary hospital staff in Tokyo who donated blood samples in June 2022 (1 month before Omicron BA.5 wave), approximately 6 months after receiving a third dose of COVID-19 mRNA vaccine. We measured live virus-neutralizing antibody titers against wild type and Omicron BA.5, and anti–receptor-binding domain (RBD) antibody titers at preinfection, and compared them between cases and propensity-matched controls. Among the breakthrough cases, we examined association between preinfection antibody titers and incidence of long COVID.

Results

Preinfection anti-RBD and neutralizing antibody titers were lower in cases than controls. Neutralizing titers against wild type and Omicron BA.5 were 64% (95% confidence interval [CI], 42%–77%) and 72% (95% CI, 53%–83%) lower, respectively, in cases than controls. Individuals with previous Omicron BA.1/BA.2 infections were more frequent among controls than cases (10.3% vs 0.8%), and their Omicron BA.5 neutralizing titers were 12.8-fold higher than infection-naive individuals. Among cases, preinfection antibody titers were not associated with incidence of long COVID.

Conclusions

Preinfection immunogenicity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may play a role in protecting against the Omicron BA.5 infection but not preventing long COVID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Post-Acute COVID-19 SyndromeCOVID-19HumansAntibodies, NeutralizingBreakthrough InfectionsCOVID-19 VaccinesPropensity ScoreSARS-CoV-2Antibodies, Viral

Stichwörter der Autor:innen

COVID-19breakthrough infectionlong COVIDneutralizing antibodyprior infectionvaccination

Substanzen

Antibodies, NeutralizingCOVID-19 VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Japan Foundation for AIDS Prevention, Tokyo, Japan.
  • Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan.
  • Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.

ORCID-Profile: Shohei Yamamoto, Tetsuya Mizoue, Norio Ohmagari

Förderung

  • Japan Health Research Promotion Bureau
  • National Center for Global Health and Medicine
  • Abbott Japan
  • Roche Diagnostics
  • Roche
  • Diagnostics

Zitieren

APA

Yamamoto, S., Matsuda, K., Maeda, K., Horii, K., Okudera, K., Oshiro, Y., Inamura, N., Nemoto, T., Takeuchi, J. S., Li, Y., Konishi, M., Tsuchiya, K., Gatanaga, H., Oka, S., Mizoue, T., Sugiyama, H., Aoyanagi, N., Mitsuya, H., Sugiura, W., & Ohmagari, N. (2023). Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad317

Vancouver

Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, et al. Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad317

BibTeX
@article{Yamamoto2023,
  author = {Yamamoto, Shohei and Matsuda, Kouki and Maeda, Kenji and Horii, Kumi and Okudera, Kaori and Oshiro, Yusuke and Inamura, Natsumi and Nemoto, Takashi and Takeuchi, Junko S and Li, Yunfei and Konishi, Maki and Tsuchiya, Kiyoto and Gatanaga, Hiroyuki and Oka, Shinichi and Mizoue, Tetsuya and Sugiyama, Haruhito and Aoyanagi, Nobuyoshi and Mitsuya, Hiroaki and Sugiura, Wataru and Ohmagari, Norio},
  title = {Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad317}
}
Kostenlos starten →